1. Show article details.

    BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

    Business Wire – 8:00 PM ET 07/29/2021

    Trial met the primary endpoint at interim analysis, with BRUKINSA significantly prolonging progression-free survival compared to chemoimmunotherapy and safety and tolerability consistent with its known profile SEQUOIA is the second positive global Phase 3 trial of BRUKINSA in chronic lymphocytic leukemia, following ALPINE in relapsed or refractory setting CAMBRIDGE, Mass.

  2. Show article details.

    BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

    Business Wire – 7:00 AM ET 07/26/2021

    Second approval for BTK Inhibitor BRUKINSA in Canada BeiGene, Ltd. (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® has been approved by Health Canada for the treatment of mantle cell lymphoma in adult patients who have received at least one p...

  3. Show article details.

    BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

    Business Wire – 12:00 AM ET 07/09/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration has conditionally approved KYPROLIS® for injection in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior t...

  4. Show article details.

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

    Business Wire – 8:00 PM ET 07/07/2021

    BeiGene (BGNE), Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD1 antibody tislelizumab for the treatment of patients with locally advanced or metastatic esophageal s...

  5. Show article details.

    PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

    Business Wire – 7:00 AM ET 07/07/2021

    Study will investigate potential activity of a novel immunotherapeutic with checkpoint inhibition as a new treatment modality Topline Phase 1 results with single-agent LYT-200 expected in the fourth quarter of 2021 PureTech Health plc (PTCHF), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, toda...

  6. Show article details.

    Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

    GlobeNewswire – 8:30 AM ET 06/30/2021

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021.

  7. Show article details.

    China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

    Business Wire – 12:00 AM ET 06/23/2021

    Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previously approved squamous histology Tislelizumab receives its first approval in liver cancer in previously treated hepatocellular carcinoma CAMBRIDGE, Mass.

  8. Show article details.

    BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

    Business Wire – 4:30 PM ET 06/18/2021

    Third approval for BRUKINSA in China and second approval in WM worldwide BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® has received conditional approval from the China National Medical Products Administration for the treatment of adult patients with Waldenström’s macroglobulinemia who have ...

  9. Show article details.

    BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

    Business Wire – 7:00 AM ET 06/17/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlimab in combination with its anti-PD-1 antibody tislelizumab, for the first-line treatment of patients with locally advanced, unr...

  10. Show article details.

    BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

    Business Wire – 3:00 AM ET 06/11/2021

    The Phase 3 ALPINE trial met the primary endpoint at interim analysis, with BRUKINSA showing superiority in investigator-assessed overall response rate versus ibrutinib Early progression-free survival and overall survival data are supportive of findings in response rate BRUKINSA demonstrated superiority in key secondary endpoint of atrial fibrillation or flutter and advantages in overall cardia...

  11. Show article details.

    BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

    Business Wire – 3:00 AM ET 06/11/2021

    BRUKINSA demonstrated long-term clinical benefits and tolerability in patients with mantle cell lymphoma and chronic lymphocytic leukemia at extended follow-up of nearly three years Tislelizumab achieved deep and durable responses in classical Hodgkin’s lymphoma with a median progression-free survival of 32 months and no new safety signals at 34-month follow-up Company to host investor call a...

  12. Show article details.

    Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

    Business Wire – 7:00 AM ET 06/09/2021

    BeiGene (BGNE) has worldwide development and commercialization rights, with Shoreline having an option to retain U.S. and Canadian rights on up to two of four targets Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer and macrophage cellular immunotherapies derived from induced pluripotent stem cells...

  13. Show article details.

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors

    Business Wire – 5:00 PM ET 06/07/2021

    BeiGene (BGNE), Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated, locally advanced unres...

  14. Show article details.

    BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting

    Business Wire – 9:00 AM ET 06/04/2021

    Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer Pamiparib showed numerically higher progression-free survival in patients with gastric cancer compared to placebo, although the results did not achieve statistical significance Pamiparib was generally well-tolerated across both trials Pa...

  15. Show article details.

    BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting

    Business Wire – 9:00 AM ET 06/04/2021

    Compared to chemotherapy, tislelizumab demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with previously treated, advanced or metastatic esophageal squamous carcinoma and a favorable safety profile Tislelizumab also demonstrated a statistically significant and clinically meaningful improvement in overall response rate in patients with...

  16. Show article details.

    Zhongchao Inc. Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai

    PR Newswire – 6:30 AM ET 06/03/2021

    SHANGHAI, June 3, 2021 Zhongchao Inc. (ZCMD), a healthcare services company offering online healthcare information, professional training and educational services, announced the on-going one-year joint project of leukemia diagnosis and treatment courses that the Company has been hosting with Beijing Bethune Charitable Foundation and BeiGene Pharmaceutical Co., Ltd., a subsidiary of BeiGene, Ltd. (BGNE). The ...

  17. Show article details.

    BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

    Business Wire – 10:00 AM ET 06/01/2021

    BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysis BRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ET CAMBRIDGE, Mass.

  18. Show article details.

    BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

    Business Wire – 7:00 AM ET 05/21/2021

    Tislelizumab combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival at the interim analysis Safety findings of tislelizumab were consistent with known risks BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Phase 3 RATIONALE 309 trial of its anti-P...

  19. Show article details.

    BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

    Business Wire – 5:00 PM ET 05/19/2021

    Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three anti-PD-1 combinations and the continuing evaluation of next-generation BTK inhibitor zanubrutinib CAMBRIDGE, Mass.

  20. Show article details.

    BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

    Business Wire – 7:00 AM ET 05/19/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration has accepted a supplemental new drug application for BRUKINSA® for the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy and granted priority review.

Page:

Today's and Upcoming Events

  • Aug
    13

    BGNE to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    08

    BGNE announced Q1 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.